Ily Yumul

Ily Yumul

Auto-generated profile, based on publicly available information

Ily Yumul

Division of Cardiology, Department of Medicine, University of Iowa, Iowa City, Iowa

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
SASaima Aslam
Saima Aslam
IYIly Yumul
Ily Yumul
MMMark Mariski
Mark Mariski
VPVictor Pretorius
Victor Pretorius
EAEric Adler
Eric Adler

10 August 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CLCathy Logan
Cathy Logan
IYIly Yumul
Ily Yumul
JCJavier Cepeda
Javier Cepeda
VPVictor Pretorius
Victor Pretorius
EAEric Adler
Eric Adler
NMNatasha Martin
Natasha Martin
Outcomes following hepatitis C virus (HCV)-viremic heart transplantation into HCV-negative recipients with HCV treatment are good. We assessed cost-effectiveness between cohorts of transplant recipients willing and unwilling to receive HCV-viremic hearts. Markov model simulated long-term outcomes among HCV-negative patients on the transplant waitlist. We compared costs (2018 USD) and health outcomes (quality-adjusted life-years, QALYs) between cohorts willing to accept any heart and those willing to accept only HCV-negative hearts. We assumed 4.9% HCV-viremic donor prevalence. Patients receiving HCV-viremic hearts were treated, assuming $39 600/treatment with 95% cure. Incremental cost-effectiveness ratios (ICERs) were compared to a $100 000/QALY gained willingness-to-pay threshold. Sensitivity analyses included stratification by blood type or region and potential negative consequences of receipt of HCV-viremic hearts. Compared to accepting only HCV-negative hearts, accepting any heart gained 0.14 life-years and 0.11 QALYs, while increasing costs by $9418/patient. Accepting any heart was cost effective (ICER $85 602/QALY gained). Results were robust to all transplant regions and blood types, except type AB. Accepting any heart remained cost effective provided posttransplant mortality and costs among those receiving HCV-viremic hearts were not >7% higher compared to HCV-negative hearts. Willingness to accept HCV-viremic hearts for transplantation into HCV-negative recipients is cost effective and improves clinical outcomes.